

Title (en)  
TREATMENT OF TUMORS BY GENETIC TRANSFORMATION OF TUMOR CELLS WITH GENES ENCODING NEGATIVE SELECTIVE MARKERS AND CYTOKINES

Title (de)  
DIE BEHANDLUNG VON TUMOREN DURCH GENETISCHE TRANSFORMATION VON TUMORZELLEN MIT GENEN, DIE FÜR SELEKTIVE, NEGATIVE MARKER UND FÜR CYTOKINE KODIEREN

Title (fr)  
TRAITEMENT DE TUMEURS PAR LA TRANSFORMATION GENETIQUE DES CELLULES TUMORALES A L'AIDE DE GENES CODANTS DES MARQUEURS SELECTIFS NEGATIFS ET DES CYTOKINES

Publication  
**EP 0722343 A1 19960724 (EN)**

Application  
**EP 94930031 A 19941004**

Priority  
• US 9411251 W 19941004  
• US 13270893 A 19931006

Abstract (en)  
[origin: WO9509655A1] A method of treating a tumor in a host which comprises administering to the host at least one expression vehicle including a first nucleic acid sequence encoding an agent which renders the tumor cells sensitive to an interaction agent, and a second nucleic acid sequence which encodes an agent which provides for the inhibition, prevention, or destruction of the growth of the tumor cells, wherein such agent is not an agent which renders tumor cells sensitive to an interaction agent. The tumor then is treated with the interaction agent. Preferably, the first nucleic acid sequence encodes a negative selective marker (such as Herpes Simplex Virus thymidine kinase), and the second nucleic acid sequence encodes a cytokine (such as Interleukin-2), and the first and second nucleic acid sequences are contained in first and second viral vectors, each of which is contained in a first producer cell line and in a second producer cell line, respectively. The producer cell lines are administered to the tumor, whereby viral particles generated by the producer cell lines infect the tumor cells. Upon administration of an interaction agent, such as ganciclovir, to the host, the tumor cells are killed.

IPC 1-7  
**A61K 48/00**; C12N 15/86; C12N 5/22; C12N 5/16; C12N 15/26; C12N 15/25; C12N 15/24; C12N 15/52; C12N 15/38

IPC 8 full level  
**C12N 15/09** (2006.01); **A61K 31/52** (2006.01); **A61K 31/70** (2006.01); **A61K 35/76** (2006.01); **A61K 38/16** (2006.01); **A61K 39/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07H 21/04** (2006.01); **C07K 14/55** (2006.01); **C12N 5/10** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP)  
**A61K 48/00** (2013.01); **A61P 35/00** (2017.12); **C07K 14/55** (2013.01); **A61K 38/00** (2013.01)

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9509655 A1 19950413**; CA 2173495 A1 19950413; EP 0722343 A1 19960724; EP 0722343 A4 19991229; JP H09504518 A 19970506

DOCDB simple family (application)  
**US 9411251 W 19941004**; CA 2173495 A 19941004; EP 94930031 A 19941004; JP 51098895 A 19941004